Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 33Docetaxel 10Nivolumab 9Paclitaxel 6Trastuzumab 5Gemcitabine 5Cetuximab 5Carboplatin 5Capecitabine 5Fulvestrant 4Cyclophosphamide 4spartalizumab 3poly ICLC 3durvalumab 3avelumab 3Oxaliplatin 3Leucovorin 3Ipilimumab 3Fluorouracil 3Cisplatin 3Biopsy 3zimberelimab 2tremelimumab 2palbociclib 2obinutuzumab 2lenvatinib 2cemiplimab 2budigalimab 2Vorinostat 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × depatuxizumab mafodotin × Breast × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡